cyrilzakka/clinical-trials huggingface dataset:
Effects of Yoga on Sodium-induced Pressor Responses in African American Adults

This investigation aims to determine the effects of a 4-week yoga intervention on sodium-induced pressor and endothelial function responses as well as markers of renal sodium handling in African American adults.


Eligibility Criteria:
Inclusion Criteria:

* African American
* Adults ages 18-60 years

Exclusion Criteria:

* pregnancy or within 60 days postpartum
* having taken blood pressure (including diuretics beta-blockers, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers) or statin medications within the past 3 months (statins have been demonstrated to reduce oxidative stress which could impact flow-mediated dilation);
* infection (viral or other) within the past 4 weeks;
* having adrenal or endocrine tumors (these could impact BP);
* renal disease defined as a glomerular filtration rate (GFR) of less than 60 (creatinine will be tested at initial screening and GFR will be calculated);
* prior myocardial infarction; vii) known coronary heart disease;
* personal history of stroke;
* heart failure;
* cardiac arrhythmias;
* chronic obstructive pulmonary disease;
* recent chest pain or dyspnea;
* orthopedic limitations that preclude the execution of yoga postures;
* current insulin dependence;
* currently taking steroid medications;
* currently undergoing chemotherapy or radiation;
* having practiced yoga or yogic breathing techniques at least once weekly consistently within the past 3 months;
* heat intolerance or electrolyte imbalances (hypo- or hyper-natremia or hypo- or hyper-kalemia).
Dexamethasone/ Erector Spinae Plane Block Analgesia in Laparoscopic Cholecystectomy

Although considered a minimally invasive procedure, laparoscopic cholecystectomy (LC) frequently results in moderate to severe immediate postoperative pain.

Although considered a minimally invasive procedure, laparoscopic cholecystectomy (LC) frequently results in moderate to severe immediate postoperative pain. In addition to predominant visceral pain, nearly half of all patients suffer from shoulder pain in the early postoperative period. The most likely reason is sub-diaphragmatic irritation, which is transmitted by the phrenic nerve, causing referred pain in the C4 dermatome. Due to multiple sources of pain, multimodal analgesia approaches have been used in the perioperative period following LC.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective LC under general anesthesia, ASA status I-II, aged from 18 to 65 years old of both sex

Exclusion Criteria:

* Contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis)
* Altered conscious level
* Pregnancy
* Body mass index (BMI \> 35)
* Advanced hepatic or renal failure
* Chronic opioid consumption
Building a Traditional Chinese Medicine Clinical Diagnosis and Treatment Database

Collecting Traditional Chinese Medicine (TCM) clinical diagnosis and treatment data, including doctor-patient dialogues, tongue diagnosis, facial diagnosis, and TCM constitution information, to construct databases for tongue diagnosis, TCM constitution, and doctor-patient dialogues. Based on artificial intelligence technology, engage in research related to the standardization and intelligentization of TCM.

The technological principles of large language models align with the empirical medical principles of Traditional Chinese Medicine (TCM), and the rise of large model technology can greatly promote the progress of TCM. However, there is currently a lack of clinical diagnosis and treatment databases with TCM characteristics for training TCM artificial intelligence(AI) large models.

At present, a large-scale tongue image database has not yet been established for modeling common TCM tongue appearances, thereby ensuring the accuracy and consistency of TCM diagnosis and promoting the objective standardization of TCM diagnostic development.

Considering the feedback from the subjects in clinical work that the TCM constitution survey questionnaire has a large volume, takes a long time, and has certain subjective issues, we plan to carry out a large-scale clinical observational study to optimize the process of TCM constitution identification.

Traditional Chinese Medicine (TCM) doctor-patient dialogues and medical record writing are essential entities generated during the TCM diagnosis and treatment process. Assisting in consultation, medical record generation, and treatment plan recommendations based on doctor-patient dialogues have significant clinical and research value. Therefore, we plan to collect a large number of doctor-patient dialogues and outpatient medical records to construct a doctor-patient dialogue database, preparing in advance for optimizing interactive large-scale TCM models.

In summary, the research on constructing a TCM clinical diagnosis and treatment database has important clinical and scientific research value. This will help to improve the standardization and normalization of TCM diagnosis and treatment, and also support the modernization and internationalization of TCM. By applying big data analysis and artificial intelligence technology, it is possible to delve deeper into TCM diagnosis and treatment information, providing richer and more accurate data resources for clinical decision-making and scientific research exploration in TCM.

Eligibility Criteria:
Inclusion Criteria:

* People who come to the hospital for physical examination and medical treatment；
* Participants voluntarily participate in the study.

Exclusion Criteria:

* Subjects with difficulty in tongue extension, communication, etc. who cannot cooperate with data collection；
* The researchers determined that there were other factors that may have forced the subjects to terminate the study.
A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)

E5501 (5 mg, 20 mg, and 40 mg) will be administered to healthy male adults in a single-center, randomized, open-label, cross-over manner. This study will consist of 2 phases including pre-randomization (before drug administration) and postrandomization (after drug administration).


Eligibility Criteria:
Inclusion criteria;

1. Non-smokers aged 20-44 at the time of informed consent,
2. BMI is between 18.5 kg/m2 and below 25 kg/m2 at screening,
3. Platelet count is between 120,000/ microliter and below 300,000/ microliter at screening and baseline
4. Subjects and their partners can agree to use medically appropriate contraception through the study period
5. Voluntarily provided written informed consent
6. Willing and able to comply with the protocol

Exclusion criteria;

1. With a past or present history of arterial thrombosis, venous thrombosis or thrombophilia
2. With a past history of clinically significant disease within 8 weeks before study drug administration or clinically significant infection within 4 weeks before study drug administration
3. With a past surgical history that may affect the pharmacokinetics of E5501
4. Suspected to have a clinically abnormal symptom or organ dysfunction that requires treatment based on the past history, complications, subjective and objective symptoms, vital signs and body weight, electrocardiograms or clinical laboratory results at screening or baseline
5. QTcF greater than 450 ms (corrected for heart rate according to Fridericia's formula) category of the 12-lead electrocardiogram at screening or baseline
NSE/Alb as a Prognostic Biomarker for Lung Cancer

The incidence and mortality rate of lung cancer is the highest in the world. Current studies have found that tumor markers, inflammatory or nutritional indicators have a good predictive value for the prognosis of patients with non-small cell lung cancer (NSCLC). Neuron specific enolase (NSE) and serum albumin (Alb) are important indicators for monitoring tumor progression and nutritional status in lung cancer patients, respectively. Previous studies suggested that the higher the NSE, the worse prognosis of NSCLC patients, while the lower the Alb, the worse the prognosis of patients with malignant tumors. Through a retrospective study, the investigators found that NAR (NSE Alb Ratio) was higher and prognosis was poorer in patients undergoing NSCLC surgery. This is better than the previous assessment indicators PLR (platelet to lymphocyte ratio), NLR (neutrophil to lymphocyte ratio), AGR (albumin to globulin ratio), NAR can better assess prognosis. Therefore, on the basis of the previous retrospective analysis, the optimal NAR cut-off value was calculated according to ROC curve, and the value was grouped into multi-center prospective cohort study, and the relationship between NAR and other clinical indicators was studied by chi-square test. Univariate and multivariate analysis of Cox proportional hazard regression model was used to determine the prognostic factors. Finally, NSCLC patients were stratified according to tumor stage and pathological classification, and the differences of survival time between high NAR group and low NAR group were compared again under different stages and types, and the different stages of NAR in NSCLC patients were further analyzed. The clinical significance of typing. By exploring and validating the relationship between NAR and the prognosis of NSCLC patients, the investigators try to establish a new prognostic index. Obviously, it has important value for clinical application.


Eligibility Criteria:
Inclusion Criteria:

* (1) pathological diagnosis of non-small cell lung cancer
* (2) 18-70 years of age and no gender restriction.
* (3) patients who were admitted for the first time and underwent routine blood tests, three lung cancer and liver function tests.

Exclusion Criteria:

* (1) pregnant or lactating women
* (2) patients with other malignancies at the same time
* (3) patients with acute and chronic inflammation, autoimmune diseases, and patients with obvious liver and renal insufficiency.
* (4) patients with incomplete clinical and pathological data.
Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)

The research team plans to administer trophic enteral feeds to infants with Neonatal Encephalopathy that are undergoing therapeutic hypothermia. The team will monitor splanchnic NIRS values and compare these values to a group of historic infants who underwent hypothermia but did not receive feeds, to investigate whether there may be a range of values that can predict safe feeding. The team will also look at some clinical outcomes including feeding tolerance, time to achieve full enteral feeds, infection rates, length of hospital stay.


Eligibility Criteria:
Inclusion Criteria:

* Subjects greater than or equal to 35 completed weeks of gestation, on the first day of life
* Birth weight greater than or equal to 1800g
* Infants diagnosed with moderate-severe encephalopathy based on the modified Sarnat scoring system
* Infants that qualify to receive Therapeutic Hypothermia as part of our unit protocol

Exclusion Criteria:

* Premature infants \< 35 completed weeks of gestation
* Infants with birth weight \< 1800g
* Patients in whom TH is contraindicated including those with major congenital anomalies, suspected chromosomal anomaly such as trisomy 13 or 18, significant / large intracranial hemorrhage, or severe coagulopathy with active bleeding.
* Parent or guardian unable or unwilling to provide consent
* Infants requiring high doses of vasopressors including Dopamine \> 10mcg/kg/min or any 2 vasopressor agents simultaneously.
* Infants with evidence of gastrointestinal ischemia as evidenced by the presence of bloody stools.
* Infants with suspicion for gastrointestinal malformation, or obstruction as evidenced by bilious emesis or abdominal distension.
* SrSO2 \< 45% within the first 24 hours of life, prior to initiation of enteral feeds.
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology

To learn about the effect of Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON) treatment on the severity of shortness of breath in patients with cancer.

Primary Objectives:

1. To determine the effect of SPOT-ON and Enhanced Usual Care on the change in intensity of dyspnea (NRS) between baseline and 24 h in hypoxemic hospitalized patients with cancer.
2. To determine the effect of SPOT-ON and Enhanced Usual Care on the change in intensity of dyspnea (NRS) between baseline and 24 h in non-hypoxemic hospitalized patients with cancer.

Secondary Objectives:

1. To determine the effect of SPOT-ON and Enhanced Usual Care on patient outcomes over 72 h, including intensity of dyspnea (NRS), unpleasantness of dyspnea (NRS), dyspnea response, ital signs, symptom burden, health-related quality of life (EQ-5D-5L), adverse events, patterns of device use, and hospital outcomes.
2. To identify factors associated with dyspnea response in the SPOT-ON intervention, including patient demographics, preferences, and level of usage of oxygen delivery modalities.
3. To identify patient factors associated with their preferences (after Phase II and Phase III) for each of the oxygen delivery modalities in the SPOT-ON intervention, such as patient demographics and dyspnea characteristics.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of advanced cancer (metastatic, locally advanced, recurrent, or incurable).
* Age 18 or older.
* Admitted to a medical floor.
* Dyspnea intensity at rest of at least 4 on a 0-10-point NRS (where 0 = none, 10 = worst).
* Speak English or Spanish.

Exclusion Criteria:

* Hemodynamic instability requiring active Merit Team or ICU team involvement.
* Delirium as per clinical team's assessment in the Electronic Health Record (EHR).
* Severe hypoxemia (SpO2 \< 90% despite supplemental oxygen of up to 6 L/min).
* Continuous positive airway pressure (CPAP) use for obstructive sleep apnea, actively using \>10 hours a day.
* Respiratory failure necessitating mechanical ventilation (i.e., HFNC or NIV), and planned thoracentesis within 72 hours of enrollment.
* Patients with known pregnancy.
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patients with renal cell carcinoma (RCC) that has spread to other parts of the body (metastatic) or is limited to the tissue or organ where it began (localized). Anti-IMP3 is a tumor marker that can be detected in many human cancers, including RCC and is likely to be present in the serum (blood) of patients with metastatic or localized RCC. Alterations in microRNA expression has also shown to play a critical role in cancer progression and may be a promising biomarker for patients with RCC. Developing a blood test for anti-IMP3 antibody and microRNA in serum and tissue samples of patients in the laboratory may help doctors find and diagnose RCC earlier, find out how far the disease has spread, and plan effective treatment for RCC.

PRIMARY OBJECTIVE:

I. To develop a blood test by monitoring the titer of IMP3 autoantibody and/or microRNA (miRNA)/small non-coding RNA (snRNA) expression in patients' serum for the early detection of RCC and its recurrence/metastasis.

OUTLINE: Serum samples are collected prior to treatment and analyzed for anti-IMP3 autoantibody titer via enzyme-linked immunosorbent assay (ELISA) and total RNA via sequencing, microarray, and/or quantitative polymerase chain reaction (q-PCR). Previously collected tissue samples are analyzed for IMP3 via immunohistochemistry (IHC).

Eligibility Criteria:
Inclusion Criteria:

Metastatic RCC Patients' Serum Cohort:

* a. Serum samples from patients with metastatic RCC prior to surgical removal of the metastatic and/or primary lesions
* b. Serum samples from patients with localized RCC prior to surgical removal of the lesions
* c. Discarded donors' and patients' discarded/leftover plasma/serum samples from blood bank and other Department of Pathology laboratories
* d. Serum samples from patients with metastatic RCC who had nephrectomies or/and RCC-related biopsies in the referring hospitals

Metastatic RCC Patients' Tissue Cohort:

* Formalin-fixed paraffin-embedded (FFPE) and/or frozen primary and/or metastatic RCC tissue samples from the corresponding patients serum who are included in inclusion criteria (a-b)
* FFPE and/or frozen benign renal tissue samples which are nearby the tumor and remove during surgical procedures from the corresponding patients who are included in inclusion criteria (a-b)
* Discarded/leftover FFPE and frozen renal tissue samples from Department of Anatomic Pathology and its Tumor Bank
* FFPE primary and/or metastatic RCC tissue samples (unstained slides) from the corresponding patients who are included in inclusion criteria (d)

Exclusion Criteria:

Not applicable
Belimumab In Early Systemic Lupus Erythematosus

To investigate the efficacy of belimumab in early SLE patients (disease duration less than 6 months).

This is a single arm, 24 weeks, pilot trial. All patients will be treated with standard of care plus Belimumab (at a dose of 10 mg per kilogram of body weight) .

The primary endpoint is the proportion of LLDAS in week 24.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of SLE according to the 1997 American College of Rheumatology (ACR) classification criteria or 2019 EULAR/ACR classification criteria within three months, which is autoantibody-positive (antinuclear antibody titers ≥1:80, anti-double-stranded DNA antibodies, or both)
* 18-75 years of age
* body weight 45-80kg
* Disease duration of SLE ≤ 6months
* SELENA-2K score ≥6 scores
* Negative pregnancy test for child-bearing women at screening and baseline
* Provide written informed consent

Exclusion Criteria:

* Known to be allergic to Prednisone Acetate, Meprednisone, Hydroxychloroquine, and Immunosuppressants including Mycophenolate Mofetil, Cyclophosphamide,et al
* Active serious neuropsychiatric systemic lupus erythematosus or other severe situations of SLE who need pulse steroid treatment
* Abnormal liver function (ALT or AST is 2 times higher than normal)
* Pregnancy or breastfeeding women;
* Have a history of malignant tumors;
* Have any serious acute, chronic or recurrent infectious disease (such as pneumonia or active stage of pyelitis, recurrent pneumonia, chronic bronchiectasis and tuberculosis)
* Chronic infections, such as Hepatitis B virus or hepatitis B and C and HIV;
* Previous visual obstruction, monocular dysfunction and cataract;
* Cardiac insufficiency with metabolic imbalance or severe high blood pressure (systolic pressure \> 160mmHg or diastolic pressure \> 100mmHg) or diabetics;
* Active hemorrhage or peptic ulcer;
* With other concommitant autoimmune disease;
* Receipt of B-cell-targeted therapy (including belimumab) within 1 year before randomization.
* Participated in other drugs clinical trials within 4 weeks.
Pain and Stress Management for People With Rheumatoid Arthritis

Self-management of rheumatoid arthritis (RA) symptoms using written emotional disclosure (ED), coping skills training (CST), or a combination of both may benefit people with RA. The purpose of this study is to determine the benefits of ED, CST, or CST and ED together in adults with RA. This study will be conducted at Wayne State University in Detroit, Michigan and Duke University Medical Center in Durham, North Carolina.

Two self-management strategies hold promise for improving the health of people with RA: ED (writing about stress, RA, and coping options) and CST (learning six pain and stress coping skills). A strategy integrating ED with CST may be more effective than either intervention alone. This study will compare the effectiveness of ED, CST, ED in combination with CST, and control groups in alleviating the symptoms of RA.

This study will last until May 2009. Participants with RA will be randomly assigned to 1 of 4 treatment groups. Each participant will receive 3 writing sessions and 8 training sessions. Group 1 will receive ED writing followed by CST; Group 2 will receive ED writing followed by arthritis education; Group 3 will receive health behavior writing followed by CST; and Group 4 will receive health behavior writing followed by arthritis education.

Participants will be evaluated at baseline and at Months 1, 4, and 12 for pain, physical disability, psychological impairment, and disease activity. In addition, participants will record daily diaries for 30 days regarding their pain, symptoms, coping, stress, and mood prior to each of the evaluations. Changes in health status over time will be compared among groups.

Eligibility Criteria:
Inclusion Criteria:

* Meet American College of Rheumatology (ACR) 1987 criteria for RA

Exclusion Criteria:

* Other disorders that would significantly affect function (e.g., lupus, chronic obstructive pulmonary disease \[COPD\], congestive heart failure \[CHF\], cancer)
* Judged by the physician to have cognitive impairment (dementia, retardation, psychosis) or illiteracy
* Has experienced recent (last 6 months) significant stressor resulting in substantial emotional instability
* Currently in psychotherapy or a formal behavioral pain management program
* Unable to walk. Participants who use walking aids are not excluded.
* Physically unable to write
Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia

The primary goal of this study is to examine the efficacy and feasibility of a mifepristone combined with misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Armenia.

Women who were deemed eligible for the study by the provider gave informed consent. They took 200 mg of mifepristone orally at the study clinic. In 24-44 hours, they returned to the clinic for induction with misoprostol. They were admitted as inpatients at the clinic and took 400 mcg of buccal misoprostol every 3 hours until the fetus and placenta were expelled. If there was no full expulsion after 10 doses of misoprostol, the provider used their discretion to determine the appropriate clinical course of action. After responding to questions about their experience with the procedure, women were discharged from the study.

Eligibility Criteria:
Inclusion Criteria:

* Pregnancy of 13-22 weeks' gestation
* Good general health
* Meeting legal criteria to obtain abortion
* Presenting with closed cervical os and no vaginal bleeding
* Live fetus at time of presentation for service
* Willingness to undergo a surgical completion if necessary
* No contraindications to study procedures, according to provider
* Woman willing and able to consent to procedure, either by reading consent document or by having consent document read to her
* Willingness to follow study procedures

Exclusion Criteria:

* Known previous transmural uterine incision
* Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
* Parity greater than 5
* Any contraindications to vaginal delivery, including placenta previa
* Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)